Metabasis Therapeutics, Inc.

Conforma Therapeutics Corporation

Stingray Therapeutics, Inc.

Beta Cat Pharmaceuticals, Inc.

Other

Sankyo Company, Limited

Gensia Sicor Inc.

Iterion Therapeutics, Inc.

Srinivas Rao Kasibhatla

Mark D Erion

K Raja Reddy

Qun Dang

M Rami Reddy

Marcus F Boehm

Marco Antonio Biamonte

Kevin Hong

Sunil Sharma

Gerard Robert Scarlato

Jiandong Shi

Edward D Robinson

Hariprasad Vankayalapati

Lin Zhang

Xiaohui Liu

Alexis Weston

Mohan Rao Kaadige

Trason Thode

Jean-Yves Le Brazidec

Seelam Venkata Reddy

Raman Kumar Kalakuntla

Tao Jiang

Harry E Gruber

Brett C Bookser

Jeffrey Scott Larson

Junhua Fan

Stephen Horrigan

Sean Konrad McHugh

Atul Agurwal

Jon Northrup

David Hurst

Ruolan Han

Atul Agarwal

Hariprasad M Vankayalapati

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof

Methods for treatment of fibrotic diseases using compounds of formula I 

Methods for treatment of fibrotic diseases

Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures; including, salts thereof that act as anti-cancer and anti-tumor agents, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Anthracene-9, 10-dione dioxime compound prodrugs and their uses

Alkynyl pyrrolo [2,3-d] pyrimidines of Formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed. 

Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors

Zearalanol compounds are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various disorders. Methods of synthesis and use of such compounds are also described and claimed.

HSP90-inhibiting zearalanol compounds and methods of producing and using same

Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed. 

Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

Heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors. 

Purine inhibitors of fructose-1,6-bisphosphatase

Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O); and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.

Purine analogs having HSP90-inhibiting activity

A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof: 

Pyrazolopyrimidines and related analogs as HSP90-inhibitors

2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

2-aminopurine analogs having HSP90-inhibiting activity

The present invention provides compounds represented by Formula I. Ris selected from hydrogen, halogen, lower alkyl, &#x2014;SR, &#x2014;OR, &#x2014;CN, and &#x2014;NHR, Ris halogen, or lower alkyl; Ris &#x2014;NHR; Ris selected from the group consisting of hydrogen, halogen, &#x2014;SR, &#x2014;OR, &#x2014;CN, &#x2014;C(O)R, &#x2014;C(O)OH, &#x2014;NO, &#x2014;NRR, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, and Ris aryl, heteroaryl, alicyclic, or heterocyclic: 

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, diastereomer, pharmaceutically acceptable salt or prodrug thereof, Wherein Ris halogen, &#x2014;OR, &#x2014;SRor lower alkyl; Ris &#x2014;NHR; Ris &#x2014;CHR&#x2014;, &#x2014;C(O)&#x2014;, &#x2014;C(S)&#x2014;, &#x2014;S(O)&#x2014; or &#x2014;S&#x2014;; and Ris aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 3 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, and the heterocyclic group is substituted with 3 to 5 substituents.

Triazolopyrimidines and related analogs as HSP90-inhibitors

Growing community of inventors

San Diego, CA, United States of America

Srinivas Rao Kasibhatla